July 2007 · Vol. 19, No. 07GYNECOLOGIC ONCOLOGY
Four recent studies add to what we understand about screening and prophylaxis for ovarian and breast Ca
|
Fast Track
Do not screen routinely for ovarian Ca—as current guidelines state, nothing in the literature necessitates this practice
Oophorectomy confers no survival advantage when performed prophylactically for benign disease
Women who have a BRCA mutation may improve their overall and cancer-specific survival with prophylactic oophorectomy
Short-term HRT after prophylactic oophorectomy in women who have a BRCA mutation won’t raise their risk of breast cancer
|
|
Karen
H.
Lu,
MDOBG MANAGEMENT Board of Editors; Associate Professor, Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston Michael
R.
Milam,
MD, MPHFellow, Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston
ObGyns perform most of the screening for cancers of the ovary and breast. The first cancer is especially lethal, though rare, and the second is especially feared among women. This update reviews screening guidelines and recent studies that may affect how we detect and prevent ovarian and breast cancers.
Among the findings:
|
